What separates good pharma companies from great ones isn't the amount of data they have. It's the quality of the biological decisions they make using their data. That starts with a real understanding of disease biology. Because you can only be confident in a decision when you understand the biology behind it. Target selection. Indication prioritization. Combination Design. Patient population prioritization. Get those right, and everything downstream improves.

Strong AI and biology capabilities tend to pull companies in one direction. They build pipelines and develop drugs. They become the competition. We chose a different path. CytoReason was built to help pharma make better decisions, not to replace pharma. We will never develop drugs. That's not a loophole. It's a deliberate design choice.

Most Phase II failures aren’t random. They’re driven by molecular signals that are visible early in development. Pharma generates enormous amounts of data, yet decisions still rely on fragmented views of biology. The gap isn’t more data. It’s turning molecular signals into a system you can actually decide with.

Biopharma doesn’t have a data problem. It has a decision problem. Billions go into generating data, but critical R&D decisions still rely on fragmented views of biology. What’s missing is a way to turn biology into something researchers can trust. The winners won’t be the ones who collect more data. They’ll be the ones who know what to do with it.

Everyone is building an AI platform. That’s not the hard part. The hard part is keeping it grounded in human biology as new data comes in. Models can improve on paper while drifting from biological reality. The platforms that stay anchored in real biology are the ones that hold up, and drive better decisions over time.

Everyone is building an AI platform. That’s not the hard part. The hard part is keeping it grounded in human biology as new data comes in. Models can improve on paper while drifting from biological reality. The platforms that stay anchored in real biology are the ones that hold up, and drive better decisions over time.

Indication selection is a portfolio decision. The right disease–target pairing can shift probability of success and portfolio value by hundreds of millions of dollars. CytoReason models disease biology to compare options side by side, earlier in development.

Proud of our Chief Scientist Shai @shenorr for bringing the world’s first map of human immune diversity to @wef’s Science House in Davos, and advancing healthcare from reactive treatment to predictive prevention.

CytoReason expands collaboration with @sanofi to advance AI-driven drug development. Grateful for the trust and partnership as we deepen use of disease models in pharma R&D. Full press release 👇 tinyurl.com/h4he5cph

CytoReason launches LINA, the first AI agent grounded in molecular data. LINA wasn’t built to make decisions for you. It was built to bring biological clarity into the moments when you have to decide. Read the press release 👇 cytoreason.com/resources/cyt…

CytoReason is #hiring. We're looking for #backend and #fullstack developers, #bioinformaticians, #immunologists and more. Find out more and apply here: cytoreason.com/career/?coref…

Tania Dubovik Perets with Elina Starosvetsky, Yasmin Admon, Shai @shenorr & others publish groundbreaking study showing immune system’s adaptability and providing evidence that interactions between immune cell types facilitate evolution of immune traits. tinyurl.com/4k9d4b34

CytoReason raises $80M in Series B from @nvidia, @pfizer, @thermofisher and others. This means we'll be able to cover more sub-populations, strengthen precision of our disease models and empower more decision-makers with AI tools for their R&D. tinyurl.com/58vmz9vv

Read more about CytoReason's new data collaboration agreement with @CrohnsColitisFn. We'll be integrating the foundation's vast datasets with CytoReason’s #IBD disease models. Read more about it here: cytoreason.com/resources/cyt…

@Cytoreason signs data collaboration with @CrohnsColitisFn Foundation to advance IBD. We'll be incorporating CCF's massive datasets - with thousands of patient intestinal biopsies and comprehensive real-world data - into our pre-computed disease models. info.cytoreason.com/ccf

New episode of "Tech on Drugs" with Prof. Eran Segal from Weizmann and co-founder Prof. Shai @shenorr - addressing precision nutrition, large-scale longitudinal data, microbiome studies, and more. Fulle episode here: cytoreason.com/podcast/

In 2023 - 21 CytoReason employees, published 19 papers in 16 different publications - Nature Immunology, Nature Cancer, Nature Communications, Nucleic Acids Research, CellReports, &more. More here: tinyurl.com/25ax2hhh #Immunology #pharma @CellReports @NAR_Open

Interview with CEO David Harel about some of the major scientific and commercial challenges our industry faces, and about one tech company's attempt to make things (a little bit) better. nocamels.com/2024/02/using-a…

Proud of our Chief Scientist Shai @shenorr for contributing to this new study by Benguigui  & Cooper et. al, now published in Cancer Cell and highlighted in Nature Reviews Immunology.  cell.com/cancer-cell/fulltex… #CancerResearch #Oncology